| |
Turnkey pharmaceutical manufacturing facilities and a 75% property tax exemption make expanding your bioscience business to Puerto Rico easier than ever. It's not what's next, it's where. Puerto Rico. .png)
|
|
Today’s Big NewsJan 31, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. 
|
|
| By Kevin Dunleavy Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation in pain relief in more than two decades. |
|
|
|
By Angus Liu The rising class of bispecifics opened up an opportunity for the Swiss pharma to re-enter the PD-1 space from a new angle. The question is: Will the company take it? CEO Vas Narasimhan has weighed in. |
By Conor Hale The company will instead pitch its outpatient procedure as an “off-ramp” for people looking to stop taking GLP-1s and maintain their weight loss. |
By Andrea Park The fight for dominance between Regeneron and Bayer’s Eylea and Roche’s Vabysmo is playing out in arenas beyond just prescription counts and sales numbers. |
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
By James Waldron Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. |
By Fraiser Kansteiner AstraZeneca is pulling the plug on a 450 million pound sterling investment at its vaccine production site in England due in large part to the reduction of a planned financial contribution from the U.K. government, the company has confirmed. |
By Fraiser Kansteiner GE HealthCare is pumping $138 million into its Carrigtwohill fill-finish site in County Cork, for a facility that will help deliver 25 million more contrast media doses per year by the end of 2027, including commercial products and those in the pipeline. |
By James Waldron Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. |
By Kevin Dunleavy AbbVie has increased its 2027 projected sales for Humira follow-ons Skyrizi and Rinvoq to a combined $31 billion. It is a $4 billion increase on the company’s previous guidance for the immunology duo. |
By Andrea Park,Gabrielle Masson This week on “The Top Line,” we zoom in on a Fierce JPM Week panel of industry experts discussing what it will take for biotechs to pull off a successful IPO in 2025. |
By Angus Liu One of the most important launches for Novartis in recent years is off with a bang. The question now is whether the company can sustain the momentum and propel Kisqali to $4 billion in sales in early-stage breast cancer. |
By Darren Incorvaia A sugar produced by soil bacteria may be able to stop the loss of skin pigment caused by vitiligo. A new study found that injecting the molecule into mice with the autoimmune disease slowed the rate of the rodents’ pigment loss and boosted the amount of pigment-protecting T cells. |
By Kevin Dunleavy Axsome Therapeutics has finally jumped all the hurdles in a challenging regulatory saga, winning approval for its oral migraine drug Symbravo. The rapid-acting treatment is approved for the acute treatment of migraine episodes. |
By Nick Paul Taylor As Thyroid Awareness Month draws to a close, GlobalData analysts have looked at how the push to catch millions of undiagnosed disorders could drive demand for drugs and diagnostics. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we zoom in on a Fierce JPM Week panel of industry experts discussing what it will take for biotechs to pull off a successful IPO in 2025. |
|
|---|
|
|
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
